Lisen announces a revolutionary epigenetics-based diagnostic method for detecting thyroid cancers especially in cytologically indeterminate cases. The clinical research was published in the Journal of Clinical Oncology (JCO), a high-impact, peer-reviewed medical journal of the American Society of Clinical Oncology (ASCO) on November 15. The study leverages Lisen's QCIGISH (Quantitative Chromogenic Imprinted Gene In-Situ Hybridization) technology which can intuitively translate the aberrant expression status of cancer-related imprinted genes into quantifiable visualized signals in the nuclei allowing for the characterization of cancer cell allelic expressions. In the current study, Lisen's AI was collectively trained and validated using biopsies from 550 patients. The QCIGISH test had a sensitivity of 100% and also could identify true negative biopsies 100% of the time. This will allow physicians to identify whether a thyroid nodule is malignant early on while confidently excluding patients from needing unnecessary surgery or treatment. The paper was a collaborative work between Lisen and researchers from various medical universities and centers including Tongji University, Jiangsu Institute of Nuclear Medicine, Taizhou People’s Hospital, Taizhou Third People’s Hospital, Nanjing First Hospital, China Medical University, University of Chinese Academy of Sciences, Henan Cancer Hospital and Southern University of Science and Technology. The paper's primary author was Dr. Huixiong Xu from the Thyroid Research Center of the Shanghai Tenth People’s Hospital, School fo Medicine, Tongji University. Dr. Mingzhao Xing of the School of Medicine, Southern University of Science and Technology was the corresponding author. The official company press release issued by Lisen was immediately picked up by various international and local media including Yahoo, China News, China Science Daily and Chinese Academy of Science.